dockets: FDA-2005-D-0140

Regulatory dockets from Regulations.gov — containers for related documents and comments in a rulemaking proceeding.

This data as json

id agency_id title docket_type last_modified object_id rin dkabstract category subtype keywords program short_title effective_date organization attrs_raw attr_source
FDA-2005-D-0140 FDA Guidance for Industry: Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry;' Nonrulemaking 2021-09-01T01:01:16Z 0b0000648043fe94   Docket Status: OPEN     ["Reentry", "Donor Deferral ", "Product Disposition", "Testing", "HCV", " Hepatitis C Virus ", "HIV-1", "Human Immunodeficiency Virus Type 1", "NAT", "Nucleic Acid Testing ", "Guidance for Industry"] CBER Guidance for Industry: Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry     {"displayProperties": [{"name": "abstract", "label": "General Information", "tooltip": "Describes an agency's specific regulatory action; equivalents: Abstract, Description, Docket Subject, Related To, Summary."}, {"name": "legacyId", "label": "Legacy ID", "tooltip": "A pre-FDMS agency specific identifier migrated from a legacy system."}, {"name": "generic", "label": "Docket Item Code", "tooltip": "An agency specific code that identifies the type of document that established the docket (regulatory action)."}, {"name": "program", "label": "Center", "tooltip": "The agency specific program associated with the docket (regulatory action); equivalents: Docket Item Code, Location."}, {"name": "shortTitle", "label": "Short Title", "tooltip": "A combination of letters and or numbers assigned to an agency's regulatory action for purposes of brevity."}], "keywords": ["Reentry", "Donor Deferral ", "Product Disposition", "Testing", "HCV", " Hepatitis C Virus ", "HIV-1", "Human Immunodeficiency Virus Type 1", "NAT", "Nucleic Acid Testing ", "Guidance for Industry"], "modifyDate": "2021-09-01T01:01:16Z", "dkAbstract": "Docket Status: OPEN", "agencyId": "FDA", "program": "CBER", "shortTitle": "Guidance for Industry: Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry", "subType2": null, "title": "Guidance for Industry: Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry;'", "generic": "D", "field1": null, "docketType": "Nonrulemaking", "petitionNbr": null, "rin": null, "organization": null, "legacyId": "2005D-0261", "subType": null, "category": null, "field2": null, "effectiveDate": null, "objectId": "0b0000648043fe94"} single_get

Links from other tables